Aurobindo Pharma Limited, a leading pharmaceutical company, has announced its unaudited financial results for the quarter ended 30 September 2026, showcasing a significant increase in revenue and profitability. The company reported its highest-ever quarterly revenue from operations, amounting to INR 10,263 crore, marking a 23.9% year-on-year growth. This impressive performance was driven by strong growth across its business segments, particularly in the US and European markets.
The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) stood at INR 2,156 crore, reflecting a 28.5% increase compared to the same quarter last year. The EBITDA margin improved by 75 basis points to 21.0%. Aurobindo’s profit before tax (PBT) rose by 32.7% to INR 1,691 crore, while the net profit for the period increased by 32.5% to INR 1,124 crore. The company also declared an interim dividend of INR 7.0 per share.
Aurobindo’s US revenue surged by 25% year-on-year to INR 4,555 crore, driven by successful integration, base business growth, and new product launches. In Europe, revenue increased by 27% to INR 3,161 crore, accounting for 31% of the company’s consolidated revenue. The growth markets segment also performed well, with revenue rising by 16% to INR 1,026 crore. Additionally, the company’s active pharmaceutical ingredients (API) segment saw a 21% increase in revenue, amounting to INR 1,162 crore.
The company received final approval for 12 products from the US Food and Drug Administration (USFDA) during the quarter, further strengthening its product portfolio. Aurobindo’s research and development expenditure for the quarter stood at INR 376 crore, up from INR 344 crore in the previous quarter. The company generated strong free cash flows of USD 146 million, maintaining a robust net cash position of USD 189 million as of 30 September 2026.
Analysts view Aurobindo Pharma’s strong quarterly performance as a testament to its strategic focus on sustainable growth and financial discipline. The company’s diversified product portfolio and successful integration of inorganic opportunities have positioned it well for future growth. As Aurobindo continues to expand its global footprint, it remains committed to providing quality and affordable healthcare solutions worldwide.
